A Retrospective Analysis of Spontaneous Adverse Drug Reactions Reports Relating to Paediatric Patients

Rosliana Rosli¹, Long Chiau Ming¹,²*, Noorizan Abd Aziz¹, Mohamed Mansor Manan¹,³*

¹ Department of Pharmacy Practice, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, Selangor, Malaysia, ² Unit for Medication Outcomes Research and Education (UMORE), Pharmacy, School of Medicine, University of Tasmania, Hobart, Australia, ³ School of Pharmacy, KPJ Healthcare University College, Nilai, Negeri Sembilan, Malaysia

* mmmanan2002@yahoo.com (MMM); longchiauming@gmail.com (LCM)

Abstract

Background

Spontaneous reporting on adverse drug reactions (ADR) has been established in Malaysia since 1987, and although these reports are monitored by the Malaysia drug monitoring authority, the National Pharmaceutical Control Bureau, information about ADRs in the paediatric patient population still remains unexplored. The aims of this study, therefore, were to characterize the ADRs reported in respect to the Malaysian paediatric population and to relate the data to specific paediatric age groups.

Methods

Data on all ADRs reported to the National Pharmaceutical Control Bureau between 2000 and 2013 for individuals aged from birth to 17 years old were analysed with respect to age and gender, type of reporter, suspected medicines (using the Anatomical Therapeutic Chemical classification), category of ADR (according to system organ class) as well as the severity of the ADR.

Results

In total, 11,523 ADR reports corresponding to 22,237 ADRs were analysed, with half of these reporting one ADR per report. Vaccines comprised 55.7% of the 11,523 ADR reports with the remaining being drug related ADRs. Overall, 63.9% of ADRs were reported for paediatric patients between 12 and 17 years of age, with the majority of ADRs reported in females (70.7%). The most common ADRs reported were from the following system organ classes: application site disorders (32.2%), skin and appendages disorders (20.6%), body as a whole general disorders (12.8%) and central and peripheral nervous system disorders (11.2%). Meanwhile, ADRs in respect to anti-infectives for systemic use (2194/5106; 43.0%) were the most frequently reported across all age groups, followed by drugs from the nervous system (1095/5106; 21.4%). Only 0.28% of the ADR cases were reported as fatal.
A large proportion of the reports were received from healthcare providers in government health facilities.

**Discussion**

ADR reports concerning vaccines and anti-infectives were the most commonly reported in children, and are mainly seen in adolescents, with most of the ADRs manifesting in skin reactions. The majority of the ADR reports were received from nurses in the public sector, reporting ADRs associated with vaccine administration. The low fatality rate of ADR cases reported could potentially be caused by reporting bias due to the very low reporting percentage from the private healthcare institutions. This study indicates that ADR rates among Malaysian children are higher than in developed countries. Constant ADR reporting and monitoring, especially in respect to paediatric patients, should be undertaken to ensure their safety.

**Background**

Adverse drug reaction (ADR) is defined as any response to a drug which is noxious and unintended, and which occurs at doses normally used in humans for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function [1]. ADRs in children are not uncommon, with the literature showing that the incidence of ADRs in children is around 9.5%, with serious reactions accounting for 12% of the total number of ADRs [2]. Despite the fact that ADRs commonly occur in children (about three times more frequently than in non-elderly adults), there is little information regarding the characteristics of ADRs in this population [3].

The information on ADRs provided by the pharmaceutical companies during the premarketing phase of drug development is inevitably minimal. Since clinical trials are conducted in a limited timeframe, some ADRs, especially serious and latent ones, may not have taken place. As a consequence, only mild/moderate or non-serious ADRs tend to be captured during the development phase[4]. In addition, due to ethical and safety issues, vulnerable populations such as children, pregnant women and the elderly are rarely included in clinical trials [5–7], raising concerns about the safety profile of these drugs in these population groups [8].

Information on the safety profiles of drugs used in real healthcare settings is, therefore, very important in assisting healthcare professionals in making clinical decisions. This information can be acquired through the reporting of ADRs and it is, therefore, crucial to encourage healthcare professionals, and the public, to report any ADR events. In order to develop a systematic database on ADRs, the WHO has initiated an international ADR collaborative pharmacovigilance centre to monitor ADRs from all over the world. Systematic data collection from all collaborative centres enables the WHO to analyse adverse events associated with the use of drugs, identify signals or emerging problems and communicate how to minimise or prevent harm.

Pharmacovigilance is defined as “the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem” [9]. In Malaysia, pharmacovigilance activities are controlled by the National Centre for Adverse Drug Monitoring, a division within the National Pharmaceutical Control Bureau (NPCB) [10]. Unlike in other countries, ADR reporting in Malaysia is done voluntarily through spontaneous reporting by healthcare professionals, medical support staff, pharmaceutical companies and consumers. The submission of ADR reports can be done online or
manually to the secretariat in the NPCB. Since the establishment of this process in 1987, a growing number of ADRs have been reported, largely due to increased awareness of the importance of ADR reporting [10].

During the study period, the total population of Malaysia comprised approximately 29.7 million inhabitants and it is estimated that 25% of these were aged from birth to 17 years old [11]. Since Malaysia is one of the countries within the WHO International Programme for International Drug Monitoring, the National Pharmacovigilance Centre should optimally send over 200 reports per million inhabitants per year to the WHO Collaborating Centre for International Drug Monitoring [12]. NPCB receives approximately 9000 to 11500 ADR reports annually, corresponding to between 300 and 387 reports per million inhabitants per year.

Although studies have been conducted on the ADRs in children reported to the international and national databases, the findings cannot be generalized to Malaysian children [13–18]. The possible reasons for these divergent findings are differences in settings, time periods, patient populations of different sizes and age groups, and different types of reporters [17]. In addition, the Malaysian healthcare system is different from that of many other countries.

Like other countries, the Malaysian healthcare system consists of two main sectors, namely the public and the private sectors. Nevertheless, the health system varies considerably from other countries in Southeast Asia since Malaysia has centralized the administration of its public sectors, which means that all the policy and programmes are centrally formulated and financed by the Ministry of Health. The public sector is fully funded by taxation and plays a major role in providing universal health services in Malaysia. In other words, patients who seek medical treatment from the government health facilities will only have to pay minimal fees as low as one Ringgit Malaysia (Malaysian currency which equivalent is to US$0.24), since other medical expenses, including the cost of the medications themselves are subsidized by the government. On the other hand the private sector is totally self-funded and patients need to pay for all their medical expenses, either by private health insurance or from their own pockets [19]. Patients who seek medical treatment in private health facilities have higher expectations and are more demanding since they are paying directly for their healthcare costs. Because of this, the private health facilities need to maintain their prestige in order to retain their current patients and attract new patients to their facilities.

To date, limited studies have been conducted on ADRs in Malaysian children. The aims of this study, therefore, were to characterize the ADRs reported in the Malaysian paediatric population and to relate the data to specific paediatric age groups. In this context, this study makes a crucial contribution to the provision of a detailed insight into the types of ADRs in Malaysian children by analysing ADRs in children reported to the Malaysian National Centre for Adverse Drug Reaction with respect to age and gender, type of reporters, suspected medicines, category of ADRs and severity of ADRs.

**Methods**

**Setting**

This was a retrospective study using the Malaysian ADR reports database, QUEST2. It is a repository governed by the National Centre for Adverse Drug Monitoring, National Pharmaceutical Control Bureau which is under the purview of Ministry of Health of Malaysia. The database or any data derived from QUEST2 are protected by relevant Malaysian laws (Control of Drugs and Cosmetics Regulation 1984). Researchers that are interested accessing this database could do so by obtaining permission from National Centre for Adverse Drug Monitoring. The QUEST2 system contains all spontaneous ADR reports in Malaysia, including those reported by healthcare professionals in government and/or private health facilities; other health...
care professionals, pharmaceutical companies and consumers. As of January 2014, the QUEST2 database contained almost 62,000 ADR reports received from all over Malaysia’s thirteen states and two federal territories. ADR reports submitted to the NPCB must include the following information: patient’s particulars, the suspected medicine(s), the presumed ADR(s) and the reporter’s details. Upon receipt of ADR reports, the information in the reports is assessed by trained staff at NPCB and all the findings in all reports are discussed at a meeting of the Malaysian Adverse Drug Reactions Advisory Committee prior to submission to the national drug control authority in Malaysia and to the World Health Organisation-Uppsala Monitoring Centre (WHO-UMC) situated in Sweden.

Approval to conduct this study was obtained from the National Institute of Health and Medical Research and Ethics Committee in the Ministry of Health, prior to implementation of the study (NMRR-14-1231-21610). Permission to access to the QUEST2 database was also granted. The data were retrieved from the QUEST2 system according to the ADR registration number that had been assigned automatically upon data entry into the database system. No informed consent were obtained prior to analysis as the patient information was already anonymized upon data entry to the database system.

Data Extraction

All national pharmacovigilance centres (of which there are now more than 80 from all parts of the world) may either use WHO Adverse Drug Reactions Terminology (WHO-ART) or Medical Dictionary for Regulatory Activities (MedDRA) terms or codes for reporting to the WHO global individual case safety report database system, Vigibase [20]. Since, the National Centre for ADR Monitoring in Malaysia has been using WHO-ART for system organ class (SOC) classification in their reporting to WHO-UMC, the same classification for SOC (WHO-ART) was used in this study. Furthermore, as one of the member countries participating in the international drug monitoring programme, NPCB utilized the WHO-UMC causality assessment system for evaluation of ADR reports.

Data were extracted from the QUEST2 ADR database into Microsoft® Excel files using the following criteria: Anatomical Therapeutic Chemical (ATC) classification of medications, active substance of the medicines, ADRs coded according to WHO Adverse Reaction Terminology (WHO-ART) at the SOC level, patient’s details (age and gender), type of reporters and severity of ADRs. Severity is defined as the intensity of a specific ADR event and can be categorized as mild, moderate, severe and fatal [21]. For the purpose of this study, in order to present the large amount of data in a comprehensive way, the medicines about which the reported ADRs were presented at ATC level 2.

The material comprised all ADR reports on children from birth to 17 years of age reported to the QUEST system from 2000 to 2013. These ADR reports were then subdivided according to the age categories based on the International Conference on Harmonisation Guidelines on Clinical Investigation of Medicinal Products in the Paediatric Population: neonates ≤ 27 days; infants ≤ 23 months; children 2–11 years; adolescents 12–17 years [22].

Reports Excluded

Screening for possible duplicates in the ADR registration number was done using the duplication tool application in Microsoft Excel 2013. Duplication of reports can occur in large compilations of data when reports of the same events are being entered by more than one person. ADR reports relating to non-Malaysian citizens and those that had not been reviewed by the Malaysian Adverse Drug Reactions Advisory Committee were excluded from the study. Other ADR reports that were excluded were reports on food supplements, traditional and veterinary
products. Reports with no information on patient’s age were also excluded from this study, along with ADRs caused by drug administration to mothers. In order to enhance the quality of the data included in this study, only ADRs with causality assessed as certain, probable or likely and possible were analysed.

Statistics
Data on ADRs according to years, gender, age group, type of reporters, suspected medicines and category of ADRs were described as frequencies and percentages. The analysis was undertaken using Microsoft Excel 2013 and IBM SPSS Version 19.

Results
Overall Characterization of QUEST2 Reports
From 2000 to 2013, NPCB received a total of 61996 reports from various sources all over Malaysia. Of these, 19.2% (n = 11932) were related to children. The following reports: ADRs with causality evaluated as either unlikely, conditional or unclassified and unassessable or unclassifiable (n = 173), ADRs due to drug administration to the mother (n = 128), non-citizen (n = 3) and non-drug products (n = 105) were excluded from the study. After exclusion of these reports, a total of 11523 (18.6%) reports remained for use in this analysis (refer to Fig 1).

Fig 1. Flow chart of methodology and ADR reports included in the present study.

doi:10.1371/journal.pone.0155385.g001
The 11523 reports received reported a total of 22237 ADRs for individuals from birth to 17 years of age during the study period. On average, from 2000 to 2007, 195 reports (range 97 to 305) were submitted per year, meaning that the overwhelming majority of reports have been submitted in recent years, with a peak in 2011 (n = 3527). The northern region of Malaysia (covering the states of Kedah, Perlis, Penang and Perak) reported the most ADRs (53.3%) followed by the central region (covering the state of Putrajaya, Kuala Lumpur, Selangor; 18.4%) and the East Coast Region (covering the states of Terengganu, Pahang, Kelantan; 10.4%). The highest number of ADRs reports was received from the state of Penang (42.4%).

Half of the reports received by the NPCB documented one ADR per report. Reports with ≥ 5 types of ADRs were commonly reported in adolescents in the 12–17 year age group. More than half (55.7%) of the ADRs reported in children were related to vaccines. In the reports where gender was known, 70.7% of the child reports concerned females. In general, female children (73.0%) were commonly seen to experience ADRs related to vaccines while the males (86.9%) were more prone to develop ADRs following drug administration.

**Gender and Age Group (Year 2000–2013 Comparison)**

Table 1 illustrates a steadily increasing trend in the number of ADR reports from 2001 to 2010 and then a sharp increment in 2011 which levelled off thereafter. The majority of the reported ADRs occurred in adolescents aged between 12 to 17 years old (63.9%), whilst the fewest ADRs were reported in the neonatal group (1.3%). For vaccines, ADRs were most commonly reported

| Variables                     | 0–27 days | 28 days - 23 months | 2–11 years | 12–17 years | Combined |
|------------------------------|-----------|---------------------|------------|-------------|----------|
| **ADR by year, n**           |           |                     |            |             |          |
| 2000                         | 1         | 19                  | 70         | 25          | 115      |
| 2001                         | 1         | 22                  | 52         | 22          | 97       |
| 2002                         | 3         | 43                  | 53         | 32          | 131      |
| 2003                         | 6         | 50                  | 65         | 40          | 161      |
| 2004                         | 4         | 49                  | 119        | 49          | 221      |
| 2005                         | 11        | 66                  | 134        | 94          | 305      |
| 2006                         | 8         | 47                  | 109        | 82          | 246      |
| 2007                         | 3         | 52                  | 138        | 93          | 286      |
| 2008                         | 13        | 100                 | 205        | 154         | 472      |
| 2009                         | 19        | 135                 | 287        | 194         | 635      |
| 2010                         | 15        | 157                 | 282        | 579         | 1033     |
| 2011                         | 26        | 182                 | 336        | 2983        | 3527     |
| 2012                         | 0         | 100                 | 383        | 1770        | 2253     |
| 2013                         | 37        | 309                 | 447        | 1248        | 2041     |
| **ADR reports, n (%)**       | 147 (1.3) | 1331 (11.5)         | 2680 (23.3) | 7365 (63.9) | 11523 (100) |
| **Gender, n (%)**            |           |                     |            |             |          |
| **Vaccines, total**          |           |                     |            |             |          |
| Female                       | 6 (0.1)   | 169 (2.8)           | 141 (2.4)  | 5633 (94.7) | 5949 (92.7) |
| Male                         | 8 (1.9)   | 205 (48.3)          | 190 (44.8) | 21 (5.0)    | 424 (6.6)  |
| Unknown                      | 1 (2.3)   | 13 (29.5)           | 21 (47.7)  | 9 (20.5)    | 44 (0.7)   |
| **Drugs, total**             |           |                     |            |             |          |
| Female                       | 55 (2.5)  | 385 (17.6)          | 954 (43.4) | 802 (36.5)  | 2196 (43.0) |
| Male                         | 71 (2.5)  | 541 (19.2)          | 1332 (47.3)| 876 (31.1)  | 2820 (55.2) |
| Unknown                      | 6 (6.7)   | 18 (20.0)           | 42 (46.7)  | 24 (26.7)   | 90 (1.8)   |

Table 1. Number of ADRs by year, gender and age groups.

doi:10.1371/journal.pone.0155385.t001
for adolescents aged between 12 and 17 years (88.3%), and more than 90% of these ADRs were experienced by female children. On the other hand, for drugs, ADRs were most frequently reported in children aged 2 to 11 years old (45.6%) and adolescents 12 to 17 years old (33.3%), with male children having a higher tendency to develop ADRs (55.2%).

Type of Reporter

More than 90% of the reports were sent by healthcare providers in government health facilities. Most of the reports were sent by nurses (36.7%) followed by pharmacists (30.2%) and doctors (21.8%). Other reporters consist of product holders (5.2%) and non-healthcare professionals (0.2%). There were only three reports from consumers. At the early phase of ADR reporting in Malaysia, most of the reports came from the doctors but the total number of reports from doctors has increased only marginally over the years. Reports received from pharmacists have increased significantly, however, until a peak in 2011. Reports from pharmacists dropped in 2012 before rising again in 2013. Reports from nurses, however, increased the most dramatically, with the first reports received from them in 2009, rising to a peak in 2011 before falling off.

System Organ Class

From the 11523 reports received by the NPCB, 22237 SOCs were reported. “Application site disorders” (32.2%) were the most commonly reported for children, followed by Skin and Appendages Disorders (20.6%), Body as a Whole General Disorders (12.8%), Central and Peripheral Nervous System Disorders (11.2%) and Gastrointestinal Disorders (8.1%). To make the findings more meaningful, the SOCs for Drugs and Vaccines were analysed separately according to children’s age groups.

Table 2 provides an overview of the reported ADRs related to vaccines and drugs classified by SOCs and distributed by age group. The total numbers of reported ADRs relating to vaccines and drugs are shown for all SOCs and age groups. From 6417 ADR reports received regarding vaccines, there were 13574 SOCs reported in the last 14 years. The most commonly reported SOCs for vaccines were Application Site Disorders (52.1%) and the other frequently reported reactions were injection site pain, injection site reaction, injection site rash and injection site pruritus Other common SOCs reported with their associated reactions were central and peripheral nervous system disorders (13.0%) (examples: dizziness and headache), body as a whole general disorders (12.5%) (examples: fever and asthenia), gastrointestinal system disorders (8.3%) (examples: nausea and vomiting) and musculo-skeletal system disorders (6.8%) (examples: myalgia and muscle weakness). All of these SOCs were mostly seen in adolescents aged 12 to 17 years old.

Up to the year 2013, there were 5106 reports received by the NPCB related to drugs, with 8663 SOCs reported, with these being most common in children aged between 2 and 11 years old (46.2%). Unlike vaccines, SOCs from skin and appendages disorders (48.5%) which frequently manifested as rash urticarial, rash maculo-papular, pruritus and rash erythematous were the most common SOCs experienced by Malaysian children. Other common SOCs and their associated reactions were body as a whole disorders (13.2%) (fever), central peripheral nervous system disorders (8.4%) (oculogyric crisis), gastrointestinal system disorders (7.8%) (vomiting and diarrhoea) and respiratory system disorders (5.1%) (dyspnoea).

Anatomical Therapeutic Chemical Classification

The most frequently reported agents belonged to the ‘Anti-infective for systemic use’ category (74.7%), and almost half of the reports were associated with vaccines (55.7%). Of these, viral
Table 2. System organ class for vaccines and drugs according to age group.

| System Organ Class (SOC) | Age of Child | Total, n |
|--------------------------|--------------|----------|
|                          | 0-27days     | 28 Days—23 Months | 2–11 Years | 12–17 Years |
| **A) Vaccines**          |              |          |           |           |
| Application Site Disorders | 0           | 84       | 147       | 6845      | 7076       |
| Central & Peripheral Nervous System Disorders | 0 | 132 | 69 | 1568 | 1769 |
| Body as a Whole General Disorders | 7 | 195 | 230 | 1264 | 1696 |
| Gastrointestinal System Disorders | 2 | 56 | 40 | 1031 | 1129 |
| Musculo-Skeletal System Disorders | 0 | 7 | 4 | 910 | 921 |
| Skin & Appendages Disorders | 14 | 135 | 46 | 182 | 377 |
| Psychiatric Disorders | 0 | 16 | 10 | 346 | 372 |
| Respiratory System Disorders | 0 | 28 | 9 | 41 | 78 |
| Secondary Term Events | 0 | 5 | 36 | 1 | 42 |
| Platelet, Bleeding & Clotting Disorders | 0 | 8 | 8 | 5 | 21 |
| White Cell & Res Disorders | 0 | 17 | 1 | 2 | 20 |
| Cardiovascular Disorders, General | 0 | 11 | 3 | 4 | 18 |
| Resistance Mechanism Disorders | 0 | 11 | 5 | 1 | 17 |
| Neonatal & Infancy Disorders | 0 | 6 | 2 | 0 | 8 |
| Heart Rate & Rhythm Disorders | 0 | 1 | 0 | 5 | 6 |
| Urinary System Disorders | 0 | 1 | 4 | 1 | 6 |
| Vision Disorders | 0 | 0 | 0 | 4 | 4 |
| Metabolic & Nutritional Disorders | 0 | 3 | 0 | 1 | 4 |
| Vascular (Extracardiac) Disorders | 0 | 1 | 1 | 1 | 3 |
| Endocrine Disorders | 0 | 1 | 1 | 0 | 2 |
| Red Blood Cell Disorders | 0 | 1 | 0 | 1 | 2 |
| Collagen Disorders | 0 | 0 | 0 | 1 | 1 |
| Hearing & Vestibular Disorders | 0 | 1 | 0 | 0 | 1 |
| Liver & Biliary System Disorders | 1 | 0 | 0 | 0 | 1 |
| **TOTAL** | 24 | 720 | 616 | 12214 | 13574 |
| **B) Drugs**           |              |          |           |           |
| Skin & Appendages Disorders | 69 | 843 | 2016 | 1276 | 4204 |
| Body as a Whole General Disorders | 10 | 139 | 551 | 447 | 1147 |
| Central & Peripheral Nervous System Disorders | 10 | 41 | 321 | 356 | 728 |
| Gastrointestinal System Disorders | 10 | 88 | 302 | 277 | 677 |
| Respiratory System Disorders | 13 | 65 | 176 | 188 | 442 |
| Urinary System Disorders | 14 | 37 | 143 | 116 | 310 |
| Psychiatric Disorders | 3 | 16 | 112 | 85 | 216 |
| Vision Disorders | 0 | 11 | 88 | 65 | 164 |
| Liver & Biliary System Disorders | 0 | 17 | 38 | 64 | 119 |
| Cardiovascular Disorders, General | 10 | 29 | 46 | 23 | 108 |
| Application Site Disorders | 2 | 7 | 38 | 34 | 81 |
| Heart Rate & Rhythm Disorders | 5 | 18 | 23 | 31 | 77 |
| Metabolic & Nutritional Disorders | 1 | 5 | 39 | 23 | 68 |
| Vascular (Extracardiac) Disorders | 1 | 17 | 24 | 19 | 61 |
| Platelet, Bleeding & Clotting Disorders | 6 | 12 | 22 | 17 | 57 |
| Musculo-Skeletal System Disorders | 0 | 0 | 15 | 33 | 48 |
| Red Blood Cell Disorders | 1 | 2 | 13 | 15 | 31 |
| White Cell & Res Disorders | 1 | 2 | 10 | 18 | 31 |
| Neonatal & Infancy Disorders | 17 | 5 | 0 | 0 | 22 |

(Continued)
vaccines contributed 52.4% of the reports followed by bacterial and viral (combined) (2.0%) and bacterial vaccines (1.3%). The largest proportion of ADR reports were received for Human papillomavirus (HPV) vaccine (87.6%). ADRs on vaccines were most frequently reported by nurses (65.6%) followed by pharmacists (15.7%). In the next stage of analysis, reports on vaccines were excluded and reports on drugs were further analysed according to age group.

Table 3 displays the number of ADRs by therapeutic group (ATC Level 1) and age groups. Of the reported ADRs, 43% concerned Anti-infective for Systemic Use (ATC group J), which was the most frequently reported across all age groups, followed by drugs from the nervous system (ATC group N) (21.4%). Other therapeutic groups, namely Musculo-skeletal System

Table 3. ADRs for drugs distributed by therapeutic group and age groups.

| Therapeutic Group (ATC Level 1)                                    | Age of Child | Total, n |
|-------------------------------------------------------------------|--------------|----------|
| Anti-infectives for Systemic Use                                  | 0-27days: 70 | 2194     |
| Nervous System                                                   | 28 Days—23 Months: 588 | 1095     |
| Musculo-Skeletal System                                          | 2—11 Years: 478 | 386      |
| Alimentary Tract & Metabolism                                    | 12—17 Years: 147 | 372      |
| Respiratory System                                               | 0-27days: 16 | 358      |
| Antineoplastic & Immunomodulating Agents                          | 28 Days—23 Months: 58 | 194      |
| Various                                                           | 2—11 Years: 111 | 115      |
| Blood & Blood Forming Organs                                     | 12—17 Years: 58 | 78       |
| Systemic Hormones Preparations (excluding Gender Hormones & Insulins) | 0-27days: 0 | 76       |
| Sensory Organs                                                    | 28 Days—23 Months: 11 | 70       |
| Cardiovascular Systems                                           | 2—11 Years: 32 | 64       |
| Dermatologicals                                                   | 12—17 Years: 33 | 59       |
| Antiparasitic Products, Insecticides & Repellents                 | 0-27days: 0 | 39       |
| Genito-Urinary System & Gender Hormones                          | 28 Days—23 Months: 1 | 6       |
| **Total, n**                                                      | 132 | 5106     |

*Note the exclusion vaccine reports in these counts*
(ATC group M) (7.6%), Alimentary Tract and Metabolism (ATC group A) (7.3%), Respiratory System (ATC group R) (7%) and Antineoplastic and Immunomodulating (ATC group L) (3.8%) were among the other common drugs reported for ADRs in Malaysian children.

The data were further analysed according to the six most common therapeutic groups in children (ATC Level 2), as shown in Table 4. The most common therapeutic groups reported for ADRs were anti-bacterials for systemic use (39.2%) followed by analgesics (9.6%). Other common therapeutic groups are anti-inflammatory and anti-rheumatic products (6.8%), anti-epileptics (6.4%), anti-neoplastic agents (3.4%), drugs for functional gastrointestinal disorders (3.5%), psycholeptics (3.1%), drugs for obstructive airway disease (3.5%), antihistamines for systemic use (2.4%) and antivirals for systemic use (2%). In terms of age, children in the 2 to 11 years age group were most commonly reported to experience ADRs from all the frequently reported therapeutic groups except for ADRs associated with musculo-skeletal drugs (n = 216) and alimentary tract and metabolism drugs (n = 170) which were more dominant in adolescents in the 12–17 years age group.

Outcomes from ADRs

Over 14 years, only 6.8% (drug, n = 676; vaccines, n = 106) of reported ADRs were categorized as severe, with a large proportion of ADRs categorized as mild or moderate. In the reports where outcomes were known, the majority of the ADRs reported for drugs (69.2%) and vaccines (10.5%) the patients recovered without sequelae. At the time of reporting, there were quite a number of ADRs concerned with drugs (20.5%) and vaccines (3%) where the patient is not yet recorded as recovered. A small proportion of fatal cases of ADRs were reported for both drugs (n = 28) and vaccines (n = 4), as shown in Table 5.

Most fatal cases of ADRs were associated with the administration of Beractant (n = 4). Other commonly reported substances for fatal ADRs were Carbamazepine (n = 2), Bacterial and Viral Vaccines Combinations (n = 2) and Gentamicin (n = 2). Other substances, as depicted in Table 5, only reported a single fatal ADR case. Most fatalities were reported in adolescents aged between 12 to 17 years old (n = 12). Children aged between 2 to 11 years and neonates reported the same number of fatalities while infants only reported four cases of fatalities.

Discussion

Overall Characterization of QUEST2 Reports

In order to facilitate standard practice across the country, public health facilities are obliged to adopt the policy and programmes set by the Ministry of Health. Apart from the limited policy and fiscal freedom afforded to the local managers, the public sector needs to achieve national performance indicators and targets that are linked to their annual budget. ADR reporting performance is one of the major national key performance indicators which is monitored by the higher authorities in the Ministry, in order to strengthen the pharmacovigilance activity in Malaysia. Unlike with the public sector, the Ministry of Health only has minimal regulatory power over the private sector [23]. Due to this lack of control over the private sector, the reporting of ADRs from private health facilities is lower than from government health facilities. In this study, more than 90% of the ADRs received were from the government health facilities. The sharp increment of ADR reporting observed from 2009 was mainly due to the surge in the number of pharmacists and nurses in public healthcare institutions [24]. Moreover, the types of drugs suspected to cause ADRs are different between the two systems since the private health facilities do not have to comply with the standard national drug formulary established by the Ministry of Health [23]. The different types of medications suspected to cause ADRs in these two forms of healthcare provision were not the focus of this study, however.
Table 4. ADRs by common therapeutic groups (ATC Level 2) and age groups.

| Therapeutic Group (ATC Level 2) | Age of Child | Total, n |
|---------------------------------|--------------|----------|
|                                 | 0-27days | 28 Days—23 Months | 2–11 Years | 12–17 Years |
| **Anti-infectives for Systemic Use** |         |           |            |            |
| Antibacterials for systemic use | 69       | 549       | 908        | 475        | 2001 |
| Antivirals for systemic use     | 0        | 28        | 58         | 20         | 106  |
| Immune sera & immunoglobulins   | 1        | 3         | 21         | 11         | 36   |
| Antimycobacterials              | 0        | 2         | 12         | 14         | 28   |
| Antimycotics for systemic use   | 0        | 6         | 11         | 6          | 23   |
| **Total, n**                    | 70       | 588       | 1010       | 526        | 2194 |
| **Nervous System**              |         |           |            |            |
| Analgesics                      | 3        | 118       | 223        | 146        | 490  |
| Antiepileptics                  | 2        | 26        | 146        | 155        | 329  |
| Psycholeptics                   | 4        | 9         | 48         | 99         | 160  |
| Psychoanaleptics                | 2        | 2         | 41         | 31         | 76   |
| Anesthetics                     | 1        | 2         | 13         | 8          | 24   |
| Other nervous system drugs      | 0        | 0         | 3          | 7          | 10   |
| Antiparkinsons                  | 0        | 0         | 3          | 2          | 5    |
| **Total, n**                    | 12       | 157       | 478        | 448        | 1095 |
| **Alimentary Tract & Metabolism** |        |           |            |            |
| Drugs for functional gastrointestinal disorders | 2     | 14        | 83         | 79         | 178  |
| Drugs for acid related disorders | 3     | 3         | 21         | 41         | 68   |
| Vitamins                        | 1        | 13        | 23         | 12         | 49   |
| Antidiarrheals, intestinal antiinflammatory/antiinfective agents | 0    | 4         | 9          | 6          | 19   |
| Mineral supplements             | 1        | 0         | 3          | 12         | 16   |
| Drugs used in diabetes          | 0        | 2         | 4          | 10         | 16   |
| Antiemetics & antinauseants     | 0        | 2         | 6          | 3          | 11   |
| Drugs for constipation          | 0        | 0         | 4          | 4          | 8    |
| Other alimentary tract & metabolism products | 0    | 0         | 2          | 2          | 4    |
| Stomatological preparations     | 0        | 0         | 1          | 1          | 2    |
| Anabolic agents for systemic use | 0     | 0         | 1          | 0          | 1    |
| **Total, n**                    | 7        | 38        | 157        | 170        | 372  |
| **Musculo-skeletal System**     |         |           |            |            |
| Antiinflammatory & antirheumatic products | 2   | 16        | 132        | 197        | 347  |
| Muscle relaxants                | 1        | 4         | 8          | 10         | 23   |
| Other drugs for disorders of the musculo-skeletal system | 0    | 0         | 3          | 6          | 9    |
| Drugs for treatment of bone disorders | 0    | 0         | 3          | 1          | 4    |
| Topical products for joint & muscular pain | 0  | 0         | 1          | 2          | 3    |
| **Total, n**                    | 3        | 20        | 147        | 216        | 386  |
| **Respiratory System**          |         |           |            |            |
| Drugs for obstructive airway diseases | 4    | 36        | 111        | 27         | 178  |
| Antihistamines for systemic use | 6        | 16        | 71         | 31         | 124  |
| Cough & cold preparations       | 1        | 5         | 20         | 15         | 41   |
| Nasal preparations              | 0        | 1         | 7          | 1          | 9    |
| Other respiratory system products | 5    | 0         | 0          | 0          | 5    |
| Throat preparations             | 0        | 0         | 0          | 1          | 1    |
| **Total, n**                    | 16       | 58        | 209        | 75         | 358  |
| **Antineoplastic & Immunomodulating Agents** |        |           |            |            |
| Antineoplastic agents           | 0        | 5         | 104        | 64         | 173  |

(Continued)
The ADR data for local children is very important and each country should have their own data on ADRs in this specific population group. Based on the national income level, classified in accordance with the World Bank Definition, Malaysia is an upper middle-income country [23]. High income countries, primarily in Europe and the US, have greater resources, competency and infrastructure to survey the safety of medicine. There is, therefore, far more information available about ADRs from high income countries. Conversely, there is only limited information about ADRs occurring in middle to low-income countries, including Malaysia [25]. Although many drugs have been extensively studied in the developed countries, their safety profile cannot necessarily be generalised to other countries, where the incidence, pattern and severity of adverse reactions may differ markedly because of local environmental and genetic influences [26, 27].

The data presented here shows that there are substantial numbers of suspected ADRs, 18.6% (vaccine: 10.4%, drugs: 8.2%) in children reported in Malaysia. This figure is close to the incidence of patients with ADRs reported in a study conducted at a public hospital located in the central region of Malaysia (16.5%) [28]. The proportion of ADRs in children from other international pharmacovigilance centres was reported to range from 7–14.2%. The designs of these studies varied, however, in terms of sampling period, children’s age classifications and reported medications [14-16, 29]. With the exception of vaccines, the proportion of ADRs related to drugs (8.2%) in this study was slightly higher than that reported worldwide (7.7%) [16]. These ADRs occur in children at all age groups, and are noted to be from the therapeutic class of ‘anti-infectives for systemic use’, particularly vaccines (55.7%), and to cause a wide variety of reactions mainly from the SOC of ‘application site disorders’ (32.2%). In addition, the time period covered in this study is sufficient to witness the emerging role of nurses in the reporting of ADRs in Malaysia. This is because the nurse is the main healthcare professional that administers vaccine to the patient; especially nurses in primary and secondary healthcare institutes, such as district hospitals and clinics. Meanwhile, the high ADR reporting in the state of Penang as compared to the other states within Malaysia is mainly due to the strong ADR reporting culture among the senior medical specialists and pharmacists in two tertiary public hospitals there. This culture feeds through to junior medical staff, including nurses, who are taught and encouraged to submit ADRs that they encounter.

### Gender and Age Groups

In this study, more than 50% of the ADRs involving children were for females, with an even greater proportion in the oldest age group (12–17 years old). Most of the ADRs (92.7%) reported were related to vaccines. The reason for this dominance was the introduction of Malaysia’s cervical cancer prevention programme instituting free HPV immunisation to 13 years old Malaysian girls, which started in 2010 [30]. Other studies have also shown female dominance for ADRs related to vaccine administration [31].

---

**Table 4. (Continued)**

| Therapeutic Group (ATC Level 2) | Age of Child | Total, n |
|-------------------------------|--------------|----------|
|                               | 0-27days     | 28 Days—23 Months | 2–11 Years | 12–17 Years |
| Immunosuppressants            | 1            | 0         | 6         | 6          | 13         |
| Immunostimulants              | 1            | 0         | 1         | 6          | 8          |
| Total, n                      | 2            | 5         | 111       | 76         | 194        |

doi:10.1371/journal.pone.0155385.004
Table 5. Characteristics of fatal ADRs.

| Suspected Agents (Drug/Vaccine) | Age | Gender | Year | Adverse Reactions (WHO-ART) |
|---------------------------------|-----|--------|------|-----------------------------|
| **Caused by ADR**               |     |        |      |                             |
| Ranitidine                      | 6 years | Female | 2000 | Respiratory depression, cardiac arrest |
| Cisplatin                       | 6 years | Male   | 2000 | Steven Johnson Syndrome, death |
| Phenytoin                       | 2 years | Female | 2001 | Bradycardia                 |
| Amoxycillin                     | 4 years | Female | 2007 | Exanthema                   |
| Imatinib                        | 17 years | Female | 2005 | Jaundice, sepsis            |
| Suxamethonium                   | 15 years | Male   | 2009 | Hypothermia, tachycardia, acidosis metabolic, hyponatremia, hypertension |
| Azithromycin                    | 15 years | Female | 2008 | Tachycardia ventricular     |
| Pneumococcal vaccine            | 7 months | Male   | 2011 | Infection streptococcal     |
| **Drug Maybe Contributory**     |     |        |      |                             |
| Beractant (4 cases)             | 1 day | 3 female, 1 male | 2011 | Pulmonary haemorrhage       |
| Metoclopramide                  | 1 month | Female | 2011 | Enterocolitis necrotising   |
| Indomethacin                    | 2 weeks | Female | 2004 | Renal function abnormal     |
| Cyclophosphamide                | 1 year | Female | 2012 | Neutropenia                 |
| Promethazine                    | 1 year | Male   | 2001 | Face oedema, dyspnoea       |
| Midazolam                       | 7 years | Female | 2003 | Apnoea                      |
| Fentanyl                        | 4 years | Male   | 2011 | Bradycardia, hypotension    |
| Doxorubicin                     | 8 years | Female | 2009 | Cardiomyopathy              |
| Diphenhydramine                 | 2 years | Male   | 2008 | Unconsciousness, seizure anoxic, respiratory depression, limpness body, muscle stiffness, cardiac arrest, eye rolling, breathing arrested |
| Carbamazepine immediate release tablet | 14 years | Male | 2009 | Toxic epidermal necrolysis |
| Carbamazepine controlled release tablet | 14 years | Male | 2009 | Toxic epidermal necrolysis |
| Sodium valproate                | 12 years | Male | 2004 | Renal failure, fever, jaundice, somnolence, rash erythematous, hepatic failure |
| Gentamicin (2 cases)            | 17 years | Male | 2004 | Renal failure acute         |
| Lenograstim                     | 17 years | Female | 2006 | Sepsis, Leukaemia acute megakaryocytic |
| Cloxacillin                     | 14 years | Female | 2007 | Rash                        |
| Ceftriaxone                     | 13 years | Male | 2008 | Hepatic enzymes increased   |
| Meropenem                       | 1 months | Male | 2005 | Diarrhoea, fever, colitis pseudomembranous, clostridial infection |
| DTP*-Hib + Hep B                | 3 months | Female | 2008 | Syncope, abnormal crying    |
| DTP*-Hib + Polio                | 2 months | Male | 2010 | Abnormal crying hypotonic-hyporesponsive episode, fits, eyes gaze upward, fever |
| Hepatitis B                     | 1 month | Female | 2009 | Vomiting, death             |

* DTP-Hib-Diphtheria, Tetanus, Pertussis and Haemophilus influenzae type b

doi:10.1371/journal.pone.0155385.t005
On the contrary, a higher reporting rate for males was reported by Rashed et al. [32]. A similar trend of higher prevalence of ADRs among males, particularly those in the 2 to 11 years age groups, was also observed in two studies that included data from European and Vigibase member countries [16, 31]. Apart from the common prevalence of certain childhood diseases such as asthma and attention deficit hyperactivity disorder among males, no definite explanation for this difference has been identified [16, 31]. Meanwhile, the current study showed a higher prevalence of ADRs among adolescents 12–17 years; in contrast to worldwide Vigibase and Danish data that mostly consist of younger age groups (≤ 2 years old) [16, 17].

Type of Reporter

The initiatives taken by the NPCB through continuous ADR awareness programmes has resulted in a steady increase of ADR reporting over the years, with the majority of the reports now received from the pharmacists [24, 33]. ADR reporting activity has been included as part of pharmacist training modules, which possibly explains the high reporting rate among pharmacists. Although physicians are traditionally the primary reporters for ADRs in children, this study shows that, in a Malaysian context, nurses reported the most ADRs [16]. The involvement of nurses in ADR reporting started in 2009 and this study discovers a dramatic increase in ADRs reporting by the nurses since 2010. Apart from ongoing awareness efforts by the NPCB, the dramatic rise of ADRs in 2010 and 2011 was a result of high reporting of ADRs related to HPV immunisation, as well as the administration of the H1N1 vaccines due to the H1N1 pandemic [34]. The same finding was reported by a study conducted in the UK, where the high volume of reports was attributed to a national immunization programme or campaign [29]. Although overall ADR reports received by the NPCB increased every year, a drop of 40% in ADRs related to vaccine administration was seen in 2012 [35]. Since paediatric ADRs mostly developed following immunisation, the low reporting of ADRs related to vaccines in that particular year has contributed to a drop of ADRs for children in 2012.

Even though, the target of more than 200 reports per million population has been exceeded, the low rate of ADR reporting among private healthcare professionals, in spite its ADRs awareness efforts, is a cause for concern and the NPCB has now extended its ADR programmes to universities and professional medical and nursing associations. Other initiatives include the development of an online reporting system and ADR reporting promotion to community pharmacists through its professional association’s bulletin [24, 35].

A study conducted among physicians in one of the university hospitals in Malaysia revealed that a high proportion of suspected ADRs were not reported due to uncertainty as to the types of reactions to report (81.4%) and a lack of awareness on the importance of ADR reporting (40%) [36]. These findings could now be obsolete, however, since this study was conducted in 2007, and there have been significant efforts to increase awareness among healthcare providers since then. Future study needs to be undertaken to assess the impact of NPCB awareness initiatives, however, and to identify factors that prohibit private healthcare providers from reporting ADR events.

System Organ Class

Unlike most studies, which utilize the MEdRA for ADR SOC classification, the WHO-ART was used in this study as this classification is used by NPCB in its routine ADRs reporting to WHO-UMC. Nevertheless, similar to other studies, the most frequently reported SOCs in children were related to skin reactions and administration site conditions, nervous system disorders and general disorders [15, 16].
Anatomical Therapeutic Chemical Classification

The data from the current study revealed that routine administration of vaccines is associated with a large number of ADR reports, dwarfing the number of reports for medications. This reflects the high usage of vaccines in the paediatric population compared with medicines. The high volume of paediatric ADR reports in respect to vaccines has also been noted in other studies reviewing national pharmacovigilance databases [15, 17, 31].

When the data were further broken down to therapeutic group (ATC Level 2), with the exception of vaccines, antibacterial drugs for systemic use appear to be the most prominent drugs suspected of causing ADRs in children, followed by drugs from the nervous system therapeutic group. Indeed, drug utilization studies of children in European countries show that the most commonly prescribed drugs are antibiotics [37]. This finding was also in line with the finding of an exploratory study on paediatric ADRs from the Vigibase system [15–17].

In the current study, the most common drugs associated with ADRs were among the most commonly utilized drugs in Malaysia as reported in the National Medicines Use Survey (NMUS), except for antivirals for systemic use and antineoplastics. The NMUS, which was designed to support the implementation of the National Medicines Policy, collects information on the supply, procurement, prescription, dispensing and use of drugs in Malaysia [38, 39]. Although information from the NMUS can be used for estimating the degree of underreporting of ADRs, and the number of people exposed to certain medications in the occurrence of ADRs, this information is inconsequential for the paediatric population. The NMUS uses Defined Daily Doses (DDD), the assumed average maintenance dose per day, as its main indication in adults in reporting drug utilization, and this makes it impossible to estimate the prevalence of drug use in paediatrics. In addition, the survey only provides information on medicines that have been procured or prescribed or dispensed, and this does not necessarily equate to medication actually consumed by patients. A national survey using information on prescribed daily dosages and indications should be initiated and compared with the DDD values so as to get accurate drug utilization figures for the Malaysian paediatric population [39–41].

Outcomes from ADRs

Similar to other studies, a large number of the ADRs reported had mild outcomes, with only a small number being severe [18]. The current study revealed that the majority of the fatal ADRs were associated with drug rather than vaccine administration. In Malaysia, there were 32 fatal ADRs (0.28%) during the study period, which was lower than reported in other published literature (0.77% - 1.15%) [15, 17]. Although other studies have shown the majority of fatal cases to occur in younger childhood, this study found more fatalities in adolescents than in younger age groups [15]. The higher proportion of fatal cases in adolescents could be a result of the higher proportion of ADRs reported to the pharmacovigilance centre for this age group which has been shown in an international multicentre study [28]. Even though anticonvulsant administration in a paediatric context has been noted to cause the highest rate of fatalities, there were only four reported fatalities associated with anticonvulsants [42].

This study presents the overall reporting of ADRs for children in the Malaysian ADR database (the QUEST2 system) and only reports the incidence of ADRs in children, types and severity of ADRs and the most common drugs associated with ADRs. The current study presents the first large-scale data on ADR reported in children nationally. Studies monitoring specific childhood age groups, especially in respect to children below 2 years old could provide more useful information since the wider literature has reported more ADRs in this population group than has been shown in the current study.
The variation of risks for ADRs in different childhood age groups, and details regarding the management of the reaction, were not studied however, since some of these data were not readily available. In addition, the possible causal association between a medicine or vaccine and the suspected ADR was not formally assessed since the study only analysed the characteristics of suspected ADRs reported to NPCB. Furthermore, the relationship between the use of off-labelled drugs and the occurrence of ADRs were not studied since the list of off-labelled drugs is not well defined in Malaysia.

The data are derived entirely from the Malaysian ADR spontaneous reporting database and are therefore subject to the limitations of any such system. Those limitations highlighted in the literature include under-reporting of ADRs, variable quality in the completion of the reporting form, reporting biases, inability to calculate the true incidence of any ADRs reported, assessment of causality between a drug and an ADR and difficulty in identifying ADRs with long latency periods following the use of a drug [42–45].

Conclusions
A sharp increase in ADR reporting in respect to children over the last 14 years was observed in Malaysia. The majority of ADRs reported for children were related to the use of vaccines and anti-infectives in adolescents. In lieu of that, the prevalence of fatality caused by reported ADRs in Malaysia is lower than the benchmark of developed countries. Most suspected ADRs were related to vaccines, which is linked to the emerging role played by nurses in the spontaneous reporting of ADRs.

Acknowledgments
The authors would like to thank the Director-General of Health Malaysia and Senior Director of Pharmaceutical Services, Ministry of Health (Malaysia) for the permission to conduct this study. We wish to thank Mr. Tan Ann Ling, Director of NPCB and staffs at National Centre for Adverse Drug Reaction Monitoring, NPCB (Sameerah Shaikh Abdul Rahman, Rokiah Isahak, Noraisiyah Mohd Sani, Nurul Huda Hamdan and Wo Wee Kee) for providing technical support. Special appreciation goes to Prof Kamaruzaman Jusoff, Faculty of Resource Science and Technology, Universiti Malaysia Sarawak (UNIMAS) and Dr Jonathan Richardson (Academic Research Editors) for reviewing and editing the manuscript.

Author Contributions
Conceived and designed the experiments: RR NAA LCM MMM. Performed the experiments: RR. Analyzed the data: RR LCM MMM. Contributed reagents/materials/analysis tools: RR LCM MMM. Wrote the paper: RR LCM MMM.

References
1. WHO. International Drug Monitoring: The Role of National Centre (pp. 1–48). 1972.
2. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001; 52(1):77–83. PMID: 11459893; PubMed Central PMCID: PMC2014499.
3. Du W, Lehr VT, Lieh-Lai M, Koo W, Ward RM, Rieder MJ, et al. An algorithm to detect adverse drug reactions in the neonatal intensive care unit. J Clin Pharmacol. 2013; 53(1):87–95. doi:10.1177/0091270011433327 PMID: 23400748.
4. Aagaard L, Soendergaard B, Stenver DI, Hansen EH. Knowledge creation about ADRs—turning the perspective from the rear mirror to the projector? Br J Clin Pharmacol. 2008; 65(3):364–76. doi: 10.1111/j.1365-2125.2007.03019.x PMID: 17961195; PubMed Central PMCID: PMC2291241.
5. Smyth RL, Weindling AM. Research in children: ethical and scientific aspects. Lancet. 1999; 354 Suppl 2:SII21–4. PMID: 10507255.

6. Sammons HM. Avoiding clinical trials in children. Arch Dis Child. 2011; 96(3):291–2. doi: 10.1136/adc.2010.203737 PMID: 21262747.

7. Nor Arpin KN, Choonara I, Sammons HM. Systematic review of safety in paediatric drug trials published in 2007. Eur J Clin Pharmacol. 2012; 68(2):189–94. doi: 10.1007/s00228-011-1112-6 PMID: 21858432; PubMed Central PMCID: PMC3256313.

8. Sammons HM, Choonara I. Clinical trials of medication in children, 1996–2002. Eur J Clin Pharmacol. 2005; 61(2):165–7. doi: 10.1007/s00228-005-0894-9 PMID: 15761753.

9. WHO. The importance of Pharmacovigilance: Safety monitoring of medicinal products (p. 7). 2002.

10. Pharmaceutical Services Division Ministry of Health Malaysia. Malaysian Guidelines for the Reporting and Monitoring of ADR. 2002. Available: http://www.bpfk.gov.my/madrac. Assessed 30 May 2015.

11. Department of Statistics Malaysia. Malaysia Statistical Handbook. (pp. 1–134). 2014.

12. WHO. Reporting Trends. WHO-Uppsala Monitoring Centre. 2015.

13. Thiessard F, Roux E, Miremont-Salamé G, Fourrier-Réglat A, Haramburu F, Tubert-Bitter P, et al. Trends in Spontaneous Adverse Drug Reaction Reports to the French Pharmacovigilance System (1986–2001). Drug Saf. 2005; 28(8):731–40. PMID: 16048358

14. Wallerstedt SM, Brunlof G, Sundstrom A. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register. Drug Saf. 2011; 34(8):669–82. doi: 10.2165/11591730-000000000-00000 PMID: 21751827.

15. Aldea A, Garcia Sanchez-Colomer M, Fernandez Quintana E, Garcia Saiz M. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009. Eur J Clin Pharmacol. 2012; 68(9):1329–38. doi: 10.1007/s00228-012-1255-0 PMID: 22415248.

16. Star K, Norén GN, Nordin K, Edwards IR. Suspected adverse drug reactions reported for children worldwide. Drug Saf. 2011; 34(5):415–28. doi: 10.2165/11587540-000000000-00000 PMID: 21513364

17. Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007. Drug Saf. 2010; 33(4):327–39. doi: 10.2165/11319100-000000000-00000 PMID: 20297864.

18. Barzaga Arencibia Z, Lopez Leyva A, Mejias Pena Y, Gonzalez Reyes AR, Fernandez Manzano E, Choonara I. Pharmacovigilance in children in Camaguey Province, Cuba. Eur J Clin Pharmacol. 2012; 68(7):1079–84. doi: 10.1007/s00228-012-1222-9 PMID: 22315149; PubMed Central PMCID: PMC3374098.

19. Jaafar S, Noh KM, Musta’alib KA, Othman N, Healy J. Chapter 2: Organization and governance. In Malaysian Health System Review. Health Syst Transit. 2013; 3(1):15–30. Available: http://iris.wpro.who.int/bitstream/handle/10665.1/5283/9789290615842_eng.pdf?sequence=1.

20. Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inform J. 2008; 42(5):409–19.

21. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992; 49(9):2229–32. PMID: 1524068.

22. International Conference on Harmonisation. Clinical Investigation of Medicinal Products in the Paediatric Population (E11). 2000. Available: http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/clinical-investigation-of-medicinal-products-in-the-paediatric-population.html. Accessed 12 Dec 2015.

23. WHO. Malaysia Health System Review. Health Syst Transit. 2013; 3(1):1–103.

24. Hadi M, Ming L. Impact of pharmacist recruitment on ADR reporting: Malaysian experience. South Med Rev. 2011; 4:55–6.

25. Aagaard L, Strandell J, Melskens L, Petersen PS, Holme Hansen E. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase. Drug Saf. 2012; 35(12):1171–82. doi: 10.2165/11631940-000000000-00000 PMID: 23072620.

26. Ellasson E. Ethnicity and adverse drug reactions. BMJ. 2006; 332(7551):1163–4. doi: 10.1136/bmj.332.7551.1163 PMID: 16709964; PubMed Central PMCID: PMC1463978.

27. Salmasi S, Khan TM, Hong YH, Ming LC, Wong TW. Medication errors in the Southeast Asian countries: a systematic review. PLoS One. 2015; 10(9):e0136545. doi: 10.1371/journal.pone.0136545 PMID: 26340679; PubMed Central PMCID: PMCPMC4560405.

28. Rashed AN, Wong IC, Cranswick N, Tomlin S, Rascher W, Neubert A. Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. Eur J Clin Pharmacol. 2012; 68(5):801–10. Epub 2011/12/15. doi: 10.1007/s00228-011-1183-4 PMID: 22166934.
29. Hawcutt DB, Mainie P, Riordan A, Smyth RL, Pirmohamed M. Reported paediatric adverse drug reactions in the UK 2000–2009. Br J Clin Pharmacol. 2012; 73(3):437–46. doi:10.1111/j.1365-2125.2011.04113.x PMID: 21988288; PubMed Central PMCID: PMCPMC3370348.

30. Malaysia MoH. Annual Report: Noncommunicable Disease (NCD) Section (pp. 1–64). 2010.

31. Blake KV, Zaccaria C, Domergue F, La Mache E, Saint-Raymond A, Hidalgo-Simon A. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance. Paediatr Drugs. 2014; 16(4):309–19. doi:10.1007/s40272-014-0076-2 PMID: 24898717.

32. Rashed AN, Wong IC, Cranswick N, Hefele B, Tomlin S, Jackman J, et al. Adverse Drug Reactions in Children—International Surveillance and Evaluation (ADVISE): a multicentre cohort study. Drug Saf. 2012; 35(6):481–94. Epub 2012/05/23. doi: 10.2165/11597920-000000000-00000 PMID: 22612852.

33. Hadi MA, Helwani R, Long CM. Facilitators and barriers towards adverse drug reaction reporting: perspective of Malaysian hospital pharmacists. J Pharm Health Serv Res. 2013; 4(3):155–8. doi:10.1111/jphs.12022

34. National Pharmaceutical Control Bureau. Annual Report, Ministry of Health Malaysia. 2011.

35. National Pharmaceutical Control Bureau. Annual Report, Ministry of Health Malaysia. 2012.

36. Aziz Z, Siang TC, Badarudin NS. Reporting of adverse drug reactions: predictors of under-reporting in Malaysia. Pharmacoepidemiol Drug Saf. 2007; 16(2):223–8. doi:10.1002/pds.1313 PMID: 16947117.

37. Sturkenboom MC, Verhamme KM, Nicolosi A, Murray ML, Neubert A, Caudri D, et al. Drug use in children: cohort study in three European countries. BMJ. 2008; 337:a2245. doi: 10.1136/bmj.a2245 PMID: 19029175; PubMed Central PMCID: PMC2593449.

38. Roughead EE, Lhazeen K, Socailine E, Bahri S, Park BJ, Holloway K. Monitoring medicines use to support national medicines policy development and implementation in the Asia Pacific region. WHO South East Asia J Public Health. 2013; 2(2).

39. Ministry of Health Malaysia. Malaysian Statistics on Medicines 2009–2010. 2010.

40. Organization WH. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2011. 2011.

41. WHO Collaborating Centre for Drug Statistics Methodology. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2016, 19th ed. World Health Organization, Oslo. 2015. Available: http://www.whocc.no/filearchive/publications/2016_guidelines_web.pdf. Accessed 10 Jan 2016.

42. Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child. 2002; 87(6):462–6. PMID: 12456539; PubMed Central PMCID: PMC1755830.

43. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006; 29(5):385–96. PMID: 16689555.

44. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998; 20 Suppl C:C40–4. PMID: 9915089.

45. Belton KJ. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group. Eur J Clin Pharmacol. 1997; 52 (6):423–7. PMID: 9342576.